Coronavirus Disease 2019-Associated Pulmonary Aspergillosis
Journal of Mycology and Infection
; 27(1):2023/08/01 00:00:00.000, 2022.
Article
in English
| Scopus | ID: covidwho-2231194
ABSTRACT
As the coronavirus disease 2019 (COVID-19) pandemic continues, a new disease, COVID-19-associated pulmonary aspergillosis (CAPA), is on the rise. CAPA is a secondary fungal infection in patients with critical COVID-19 receiving mechanical ventilation in intensive care units (ICUs). Although the incidence rate of CAPA is estimated to be 10.2% in ICU patients, CAPA appears to be associated with an increase in overall mortality. CAPA is like classical invasive pulmonary aspergillosis (IPA) but has an ambiguous clinical manifestation and occurs without typical host factors. It is also like influenza-associated pulmonary aspergillosis but differs in clinical characteristics. For research and clinical practice, the European Confederation for Medical Mycology and the International Society for Human and Animal Mycology proposed novel case definition criteria for CAPA. Although CAPA management is not much different from typical IPA, areas of uncertainty remain that require further investigation. Copyright © 2022 by The Korean Society for Medical Mycology. All right reserved.
Full text:
Available
Collection:
Databases of international organizations
Database:
Scopus
Type of study:
Observational study
/
Prognostic study
Language:
English
Journal:
Journal of Mycology and Infection
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS